Celgene’s Revlimid Approved For Third-Line Use In Mantle Cell Lymphoma
This article was originally published in The Pink Sheet Daily
Executive Summary
Lenalidomide becomes first oral therapy approved in this disease but soon could be joined by ibrutinib, Pharmacyclics/J&J’s investigational agent that has received FDA “breakthrough therapy” designation.